IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Immuron Ltd Develops oral antibodies from bovine colostrum for digestive and immune health.	United States of America	IMRN
IMPACT BIOMEDICAL INC. Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.	United States of America	IBO
Imunon, Inc. Developing DNA-based immunotherapies for oncology and infectious diseases.	United States of America	IMNN
Incanthera plc Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.	United Kingdom	INC
INCYTE CORP Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.	United States of America	INCY
Indaptus Therapeutics, Inc. Develops immunotherapies using engineered bacteria to treat cancer and viral infections.	United States of America	INDP
Indivior PLC Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.	United Kingdom	INDV
INDIVIOR PLC A pharmaceutical firm developing medicines for addiction and serious mental illnesses.	United States of America	INDV
Infant Bacterial Therapeutics Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.	Sweden	IBT
InflaRx N.V. Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.	United States of America	IFRX